Impact of comorbidities after radical cystectomy using an AI-based predictive method

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study uses a predictive approach that combines artificial intelligence and clinical data to understand how non-cancer health conditions affect decisions at the urologic oncology team and patient outcomes after radical cystectomy for bladder cancer. The project aims to quantify how comorbidities and provider judgment influence guideline adherence and survival, using methods like cumulative incidence to account for competing mortality risks. Data are analyzed to identify patients at higher risk of early death and to inform more tailored treatment guidelines. The study is centered at CHU Amiens with collaboration from local oncology teams, evaluating real-world practice patterns and outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 years and older
* Patient treated by radical cystectomy for bladder cancer

Exclusion Criteria:

* Computed tomography/magnetic resonance evidence of distant metastases.

Where it's running

• CHU Amiens Picardie
  Amiens, Picardie, France Recruiting

Study contacts

• Study coordinator: Fabien SAINT, Pr
• Email: saint-fabien@chu-amiens.fr
• Phone: 03 22 45 59 52

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Deep-learning ultrasound system for precise diagnosis of bladder tumors

  This project will try a deep-learning system that reads ultrasound images to automatically segment bladder tumors, estimate T-stage, and predict tumor grade for adults with suspected bladder masses.

  Recruiting Peking University First Hospital · Beijing · NCT07111364

• AI-guided ultrasound and MRI staging to guide bladder cancer treatment

  This project will test whether a deep-learning system using ultrasound, MRI, and pathology can more accurately stage bladder cancer and predict who will benefit from additional chemotherapy for patients with suspected bladder tumors.

  Recruiting Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07051083

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.